Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
MASH/MASLD Resource Toolkit
What’s in a name? NAFLD is now MASFLD
The Fatty Liver Foundation, FIB-4 Index. Accessed October 3, 2024.
Fibrosis-4 (FIB-4) Index for Liver Fibrosis - “When to Use”, “Why To Use,” and “Pearls and Pitfalls”
Global incidence and prevalence of nonalcoholic fatty liver disease
Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Mechanisms of NAFLD development and therapeutic strategies
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
Nonalcoholic steatohepatitisdiagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey
MASLD requires multidisciplinary care to ‘improve global metabolic, liver health’
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
(
PDF
: Depending on your browser settings, file will either open in new window or download to your computer)
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
Click
here
to take the survey and receive your certificate.